Aspirin enteric-coated tablets

①Analgesic effect: It is mainly through inhibiting the synthesis of prostaglandins and other substances that can make pain sensitive to mechanical or chemical stimulation (such as bradykinin, histamine), and it is a peripheral analgesic. However, the possibility of central analgesia (possibly acting on the hypothalamus) cannot be ruled out; ②Anti-inflammatory effect: The exact mechanism is still unclear. It may be due to the fact that this product acts on inflamed tissues and inhibits the synthesis of prostaglandins or other substances that can cause inflammatory reactions (such as histamine) to play an anti-inflammatory role. Inhibition of the release of lysosomal enzymes and leukocyte chemotaxis may also be related to it; ③Antipyretic effect: It may act on the hypothalamic temperature regulation center to cause peripheral vasodilation, increased skin blood flow, sweating, and increased heat dissipation to play an antipyretic role. This central effect may be related to the inhibition of prostaglandin synthesis in the hypothalamus; ④Anti-rheumatic effect: The anti-rheumatic mechanism of this product, in addition to antipyretic and analgesic effects, is mainly anti-inflammatory; ⑤Inhibition of platelet aggregation: It works by inhibiting platelet cyclooxygenase and reducing the production of prostaglandins.

Aspirin. Chemical name: 2-(acetoxy)benzoic acid, molecular formula: C9H8O4, molecular weight: 180.2

This product is an enteric-coated tablet, which appears white after removing the coating.

Inhibit platelet aggregation, prevent thrombosis, treat and prevent transient ischemic attack, cerebral thrombosis, coronary heart disease, myocardial infarction, migraine, artificial heart valves, arteriovenous leakage and other post-operative thrombosis, thromboangiitis obliterans, etc.

1 Oral dosage for adults. ① Antipyretic and analgesic, 0.30.6g once, 3 times a day, once every 4 hours if necessary. ② Anti-rheumatic, 3-6g a day, divided into 4 times orally. ③ To inhibit platelet aggregation, a small dose should be used, such as 80g-300mg per day, once a day. ④ Treatment of biliary ascariasis, 1g once, 2-3 times a day, for 2-3 consecutive days; discontinue use after 24 hours of paroxysmal colic, and then perform anthelmintic treatment. 2 Oral dosage for children ① Antipyretic and analgesic, 1.5g/m2 per day, divided into 4-6 times orally, or 5-10mg/kg per day, or 60mg per year per day, once every 4-6 hours if necessary. ② Anti-rheumatic, 80-100mg/kg per day, divided into 3-4 times. If no effect is achieved in 1-2 weeks, the dose can be adjusted according to the blood concentration.

The doses generally used for antipyretic and analgesic rarely cause adverse reactions. Long-term and large-scale use of the drug (such as treatment of rheumatic fever), especially when the blood concentration of the drug is >200μg/ml, is more likely to cause adverse reactions. The higher the blood concentration, the more obvious the adverse reactions. (1) Gastrointestinal reactions such as nausea, vomiting, upper abdominal discomfort or pain (caused by the direct stimulation of the gastric mucosa by this product) (incidence rate 3% to 9%) are common, which can disappear after stopping the drug. Long-term or large-dose use may cause gastrointestinal bleeding or ulcers. (2) Central nervous system: reversible tinnitus and hearing loss occur, which often occur after a certain course of treatment and the blood concentration reaches 200-300g/L. (3) Allergic reaction: occurs in 0.2% of patients, manifested as asthma, urticaria, angioedema or shock. Most of them are susceptible people, and they quickly develop breathing difficulties after taking the drug. Severe cases can cause death, which is called aspirin asthma. Some are aspirin allergy, asthma and nasal polyps, which are often related to genetic and environmental factors. (4) Damage to liver and kidney function is related to the dosage, especially when the dosage is too large and the blood drug concentration reaches 250μg/ml. The damage is reversible and can be restored after stopping the drug. However, there are reports of renal papillary necrosis. (5) Symptoms of overdose or poisoning: ① Mild, namely salicylic acid reaction (salicylism), which is more common in patients with rheumatism treated with this product, and manifests as headache, dizziness, tinnitus, deafness, nausea, vomiting, diarrhea, drowsiness, mental disorder, sweating, deep and rapid breathing, thirst, involuntary movements of hands and feet (more common in the elderly) and visual impairment; ② Severe, hematuria, convulsions, hallucinations, severe mental disorder, dyspnea and unexplained fever may occur; mental and respiratory disorders are more obvious in children; in case of overdose, laboratory tests may show abnormal EEG, changes in acid-base balance (respiratory alkalosis and metabolic acidosis), hypoglycemia or hyperglycemia, ketonuria, hyponatremia, hypokalemia and proteinuria.

1. Patients who are allergic to this product are prohibited from using it. 2. Patients who are prohibited from using this product are prohibited from using it in the following situations: ① Active ulcer disease or gastrointestinal bleeding caused by other reasons; ② Hemophilia or thrombocytopenia; ③ Patients with a history of allergy to aspirin or other non-steroidal anti-inflammatory drugs, especially those with asthma, neuroangioedema or shock.

Precautions for children: Pediatric patients, especially those with fever and dehydration, are prone to toxic reactions. The use of this product in children with acute febrile diseases, especially influenza and chickenpox, may be associated with the development of Reye's syndrome, which is rare in China. Precautions for pregnancy and lactation: This product easily passes through the placenta. Animal experiments show that the use of this product in the first 3 months of pregnancy can cause teratogenesis, such as spina bifida, skull cleft, facial cleft, leg deformity, and incomplete development of the central nervous system, internal organs and bones. There are also reports of fetal defects in humans after the use of this product. In addition, long-term and large-scale use of this product in the last 3 months of pregnancy can prolong the pregnancy period and increase the risk of post-term labor syndrome and antepartum hemorrhage. Use in the last 2 weeks of pregnancy can increase the risk of fetal hemorrhage or neonatal hemorrhage. Long-term use of the drug in the late pregnancy may also cause the fetal ductus arteriosus to contract or close early, leading to persistent pulmonary hypertension and heart failure in the newborn. It has been reported that excessive use or abuse of this product in late pregnancy has increased the incidence of stillbirth or neonatal death (possibly due to ductus arteriosus atresia, antepartum hemorrhage or low body weight). However, the above adverse reactions have not been found in general therapeutic doses. This product can be excreted in breast milk. When lactating women take 650 mg orally, the drug concentration in breast milk can reach 173-483 μg/ml after 5-8 hours. Therefore, long-term high-dose medication may cause adverse reactions in infants. Precautions for the elderly: Elderly patients are prone to toxic reactions when taking this product due to decreased renal function.

(1) The efficacy of this product is not enhanced when used with other non-steroidal anti-inflammatory analgesics, because this product can reduce the bioavailability of other non-steroidal anti-inflammatory drugs. In addition, gastrointestinal side effects (including ulcers and bleeding) are increased; in addition, due to the enhanced inhibitory effect on platelet aggregation, the risk of bleeding in other parts may also be increased. Long-term and large-scale use of this product with acetaminophen may cause kidney diseases including renal papillary necrosis, renal cancer or bladder cancer. (2) When used with any drug that can cause hypoprothrombinemia, thrombocytopenia, reduced platelet aggregation function or gastrointestinal ulcer bleeding, there may be a risk of aggravating coagulation disorders and causing bleeding. (3) When used with anticoagulants (dicoumarol, heparin, etc.) and thrombolytic drugs (streptokinase, urokinase), the risk of bleeding may be increased. (4) Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in urine, causing a decrease in blood drug concentration. However, when the blood concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood concentration of this product may rise to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which not only reduces the blood concentration but also increases the amount of this product that penetrates into the brain tissue, thereby increasing toxic reactions. (5) Uric acid drugs can reduce the excretion of this product and increase its blood concentration. Patients whose blood concentration of this product has reached a stable state may increase the blood concentration of this product and increase toxic reactions after adding uricidifying drugs. (6) Glucocorticoids (hormones for short) can increase the excretion of salicylates. In order to maintain the blood concentration of this product when used together, the dose of this product should be increased if necessary. This product and hormones are used together for a long time. Especially when used in large quantities, there is an increased risk of gastrointestinal ulcers and bleeding. For this reason, it is not recommended to use these two drugs at the same time in clinical practice. (7) The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using them together with this product. (8) When used with methotrexate (MTX), it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. (9) The uric acid excretion effect of probenecid or sulfinpyrazone can be reduced by the simultaneous use of this product; when the blood concentration of salicylate is 50μg/ml, it is significantly reduced, and it is even more so when it is >100-150μg/ml. In addition, probenecid can reduce the clearance rate of salicylate from the kidneys, thereby increasing the latter's blood concentration.

Keep away from light, sealed and stored in a dry place.

25 mg

60 months, do not use after the expiration date.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

• Founded in:

  2000-09-28

• Address:

  No. 71, Menglong Street, South District, Zhengding County High-tech Industrial Development Zone, Zhengding Area, China (Hebei) Pilot Free Trade Zone

• Tax NO.:

  91130100732914772Y

• Registered Funds:

  919.060878 yuan

• Website:

  Log in to view

• Email:

  Log in to view